DGAP-News: Biotest AG: Biotest presented promising data on next generation recombinant Factor VIII at ISTH 2020
Biotest unveiled functional data from its new Factor VIII compounds at the ISTH 2020 congress (International Society on Thrombosis and Haemostasis).
DGAP-News: Biotest AG / Key word(s): Research Update Biotest AG: Biotest presented promising data on next generation recombinant Factor VIII at ISTH 2020 21.07.2020 / 07:00 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest presented promising data on next generation recombinant Factor VIII at ISTH 2020
Dreieich, 21 July 2020. Biotest unveiled functional data from its new Factor VIII compounds at the ISTH 2020 congress (International Society on Thrombosis and Haemostasis). The content of the oral presentation and three scientific posters on its innovative compounds HAT (Haemophilia A Therapeutic) and HAT RI (Haemophilia A Therapeutic Reduced Immunogenicity) is available at Biotests homepage: HAT and HAT RI address the three major challenges of current Factor VIII products for haemophilia A therapy, which are the short Factor VIII half-life, the intravenous application route and the high risk for inhibitor development. The molecules demonstrate a great potential for subcutaneous administration, evidenced by a high bioavailability of 50% observed in the "Göttingen minipig model". Results from further animal models support a 4-fold extension of the half-life in blood circulation while maintaining the wild-type characteristics of activated Factor VIII with full in vivo functionality. Thus, a substantially decreased administration frequency can be expected. The specific design of HAT and HAT RI shall confer lowest immunogenicity and reduced risk of inhibitor development, which is further enhanced by specific de-immunizing modifications in the HAT RI variant. Biotest is currently looking for a partner in order to accelerate further development. About HAT About Haemophilia About Biotest IR contact PR contact Business development contact Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 Disclaimer
21.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 - 8 01-0 |
Fax: | 0 61 03 - 8 01-150 |
E-mail: | [email protected] |
Internet: | http://www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1097773 |
End of News | DGAP News Service |
|
1097773 21.07.2020